Report calls for European funding reform for gene therapies

New payment models, dedicated investment, and better health technology assessment are among a raft of changes needed to bring regenerative medicines to patients in Europe, according to a ne

NICE clears front-line NHS use for Pfizer’s lung cancer drug...

AZ appeals against NICE rejection of Tagrisso in untreated l...

AstraZeneca is appealing against NICE’s decision not to recommend funding for its lung cancer drug Tagrisso (osimertinib) in untreated patients with epidermal growth factor receptor (EGFR)

NICE backs Alimera’s three-year uveitis implant

An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that can cau

It’s good to talk, NICE says to pharma industry group

NICE has entered into a new dialogue with industry to highlight the benefits of its early scientific advice service.

NHS England improves offer to Vertex over CF drugs

NHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to give patients access to cystic fibrosis (CF) medicines.